Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026131 | 0.84 | KMT2A (0.49) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL21815741 | 0.81 | PTPN1 (0.57) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL4570567 | 0.79 | KMT2A (0.75) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL557321 | 0.79 | MAPT (0.51) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL62862 | 0.79 | KMT2A (0.75) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL8742866 | 0.79 | TDP1 (0.57) | MAPTKMT2ATRPV1LMNAADRB2 | |
| SCHEMBL6964934 | 0.79 | GAA (0.53) | MAPTKMT2AMEN1LMNACES2 | |
| SCHEMBL21953575 | 0.79 | KMT2A (0.51) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL555991 | 0.79 | KMT2A (0.51) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL8743221 | 0.79 | HPGD (0.56) | MAPTKMT2AMEN1LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | claimed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | claimed |
| EP-1751087-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005121069-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | claimed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008034087-A2 | TREATING SCHIZOPHRENIA WITH COMBINATIONS OF LEVODOPA AND AN ANTIPSYCHOTIC AGENT | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-5972955-A | ANTITUMOR AGENTS TREATING CANCER, VIRICIDES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-10-26 | — | — | US | disclosed |
| EP-0906316-A1 | NOVEL WATER-SOLUBLE ANALOGUES OF 20(S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906317-A1 | NOVEL WATER-SOLUBLE C-RING ANALOGUES OF 20(S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-07 | — | — | EP | disclosed |
| EP-0847397-A1 | NOVEL WATER-SOLUBLE C-RING ANALOGUES OF 20 (S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997046563-A1 | NOVEL WATER-SOLUBLE C-RING ANALOGUES OF 20 (S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997046562-A1 | NOVEL WATER-SOLUBLE C-RING ANALOGUES OF 20(S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997046564-A1 | NOVEL WATER-SOLUBLE ANALOGUES OF 20(S)-CAMPTOTHECIN | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | MAPT 1341/4885KMT2A 1568/4885MEN1 1821/4885 |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | MAPT 1341/4885KMT2A 1568/4885MEN1 1821/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | MAPT 1341/4885KMT2A 1568/4885MEN1 1821/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | MAPT 1341/4885KMT2A 1568/4885MEN1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.